1. Cucinotta D, Vanelli M. WHO declares COVID-19 epidemic as Acta Biomed 2020; 91:157–160.
2. Callway e, Cyronski D, Mallapatti S, Stoy e, Tolfson J. Coronovirus epidemics in five powerful charts. Nature 2020; 579:482–483.
3. Hoffman m, Klein-weber h, Schroeder S, and others. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by clinically proven protease inhibitors. Cell 2020; 181 (2):271.e8–280.e8.
4. Amanat F, Kramer F. SARS-CoV-2 Vaccines: Status Report Immunity 2020; 52:583–589.
5. Mulligan MJ, Of lyke, Kitchen Ann, and others. Phase 1/2 study to describe the safety and immunity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults between 18 and 55 years of age: interim report. July 1, 2020 (Https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1). Preprint.
6. Corbett KS, Edwards de, Artist sr, and others. SARS-CoV-2 mRNA vaccine prototype competent development by prototype pathogen. June 1 1, 2020 (Https://www.biorxiv.org/content/10.1101/2020.06.11.145920v1). Preprint.
7. U j, Tostanowski LH, Peter el, and others. DNA vaccine protection against SARS-CoV-2 in rhesus macas. Science 2020 May 20 (Epub ahead of print).
8. Smith TRF, Patel A, Ramos S, and others. Immunity of a DNA vaccine candidate for COVID-19. Nut commune 2020; 1 1:2601–2601.
9. Zhu FC, Li ya, Guan XH, and others. Protective tolerance of a recombinant adenovirus type-5, and immunodeficiency COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial. Knife 2020; 395:1845–1854.
10. Van dormellen en, Lambe Tea, Spencer a, and others. ChAdOx1 nCoV-19 vaccination inhibits SARS-CoV-2 pneumoniae in rhesus macaques. May 13, 2020 (Https://www.biorxiv.org/content/10.1101/2020.05.13.093195v1). Preprint.
1 1. Sing q, Bao l, Mao h, and others. Development of an inactive vaccine candidate for SARS-CoV-2. Science 2020; 369:77–81.
12. Wang h, Zhang Wai, Huang Bi, and others. Development of an inactive vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. June 6, 2020 (Https://www.sciencedirect.com/science/article/pii/S0092867420306954).
13. Chen WH, Strike you, Hotez PJ, Botaji has given me. SARS-CoV-2 Vaccine Pipeline: An Overview. Cour Trop Made Rape 2020 March 3 (Epub ahead of print).
14. Munster vj, Feldman F, Williamson earned his B.N., and others. Respiratory diseases and viruses in response macaques that are infected with SARS-CoV-2. March 21, 2020 (Https://www.biorxiv.org/content/10.1101/2020.03.21.001628v1). Preprint.
15. Of Bahl, Sunny JJ, Yuzhkov O, and others. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against HRNAN8 and H7N9 influenza viruses. Mole Ther 2017; 25:1316–1327.
16. Jackson la, Anderson EJ, Raufel N.G., and others. An mRNA vaccine against SARS-CoV-2 – preliminary report. Ann Engl J Med. DOI: 10.1056 / NEJMoa2022483.
17. Hassett KJ, Of benenato, Jacquinn e, and others. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acid 2019; 15:1–1 1.
18. Wolfel R, Korman VM, Guggemos w, and others. Virological evaluation of hospitalized patients with COVID-2019. Nature 2020; 581:465–469.
19. Wang f, Falangon J, Sun, and others. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagnosis 2012; 14:22–29.
20. Ho yaz, Okuda’s, Edwards CE, and others. SARS-CoV-2 reverse genetics reveals a variable infection diathesis in the respiratory tract. Cell 2020; 182 (2):429–446.e14.
21. Scoby tea, Yount BL, Sims AC, and others. Reverse genetics of the Middle East respiratory syndrome coronavirus with a full-length infectious cDNA. Proc Natl Acad Science USA 2013; 110:16,157–16,162.
22. Yount b, Curtis KM, Fritz EA, and others. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Science USA 2003; 100:12995–13000.
23. Donaldson MM, Cao SF, Foulds Kei. OMIP-052: an 18-color panel for measuring Th1, Th2, Th17 and Tfh responses in rhesus macas. Cytometry a 2019; 95:261–263.
24. Mr. Finak, McDavid A, Chattopadhyay P, and others. Mixture models for single-cell assays with applications to vaccine studies. Biostatistics 2014; 15:87–101.
25. Pulsen J, Wang An, Corbett KS, and others. Immunogenicity and structures of a rationally designed prefabricated MERS-CoV spike antigen. Proc Natl Acad Science USA 2017; 114:E7348–E7357.
26. Wrap d, Wang An, Corbett KS, and others. The EMo-EM structure of the 2019-nCoV spike in the assumption structure. Science 2020; 367:1260–1263.
27. Wang L, Xi and, Chapel JD, and others. The importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on Middle East respiratory syndrome coronovirus spike glycoproteins to avoid minimization. Jay Virol 2018; 92 (10):e02002-17–e02002-17.
28. Wang An, Rosen O, Wang L, and others. Structural definition of a neutralization-sensitive epitope on MERS-CoV S1-NTD. a sales representative 2019; 28 (13):3395.e6–3405.e6.
29. Chen Wai, Lu S, Jia H, and others. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerg microbe infection 2017; 6 (5):E37–E37.
30. Rogers TF, Zhao F, Huang De, and others. Isolation of potent SARS-CoV-2 neutralizing antibodies and disease protection in a small animal model. Science 2020 June 15 (Epub ahead of print).
31. Head, Sh, Duan x, and others. A human neutralizing antibody targets the receptor-binding site of the antibody SARS-CoV-2. Nature 2020 May 26 (Epub ahead of print).
32. Wang w, Wang h, Deng Wai, and others. Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China. Emerg microbe infection 20165 (11):e113–e113.
33. Vidyaja Pratham, Wang Si, Van heparan r, and others. Towards a solution of MERS: protective human monoclonal antibodies targeting various domains and functions of the MERS-coronavirus spike glycoprotein. Emerg microbe infection 2019; 8:516–530.
34. Niddleman Jay, Luo x, Frouard j, and others. SARS-CoV-2-specific T cells exhibit distinct features characterized by strong helper actions, which are lack of terminal differentiation and high proliferation capacity. June 8, 2020 (Https://www.biorxiv.org/content/10.1101/2020.06.08.138826v1). Preprint.
35. Viscoff de, Schmitz K.S., Radsen is MP, and others. Phenotypes and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Science immunol 2020; 5:eabd2071–eabd2071.
36. McKiff BJ, Ramirez-Suestegui Si, Fajardo V, and others. Single-cell transcriptional analysis of SARS-CoV-2 reactive CD4 + T cells. June 13, 2020 (Https://www.biorxiv.org/content/10.1101/2020.06.12.148916v1). Preprint.
37. Griffony A, Viscoff de, Ramirez S.I., and others. Targets of T cell responses to SARS-CoV-2 coronaviruses in humans with COVID-19 disease and unaffected individuals. Cell 2020; 181 (7):1489.e15–1501.e15.
38. Peng Wai, Mentor AJ, Liu Ji, and others. Comprehensive and strong memory CD4+ And cd 8+ T cells induced by SARS-COV-2 in COLID-19 patients in the UK. June 8, 2020 (Https://www.biorxiv.org/content/10.1101/2020.06.05.134551v1). Preprint.
39. Secan tea, Perez-Poti A, Riviera-Ballesteros o, and others. Robe T. Immunity in convulsive individuals with asymptomatic or benign COVID-19. June 29, 2020 (Https://www.biorxiv.org/content/10.1101/2020.06.29.174888v1). Preprint.
40. Zou l, Ruan F, Huang M, and others. SARS-CoV-2 viral load in upper respiratory samples of infected patients. N angle j med 2020; 382:1177–1179.
41. Chandrasekhar A, Liu Jie, Martinot AJ, and others. SARS-CoV-2 infection prevents recall in rhesus macaques. Science 2020 May 20 (Epub ahead of print).
42. Rockux b, Kuiken Tea, Harfest s, and others. Comparative pathogenesis of COVID-19, MERS and SARS in an inhomogeneous intimate model. Science 2020; 368:1012–1015.
43. Edridge awd, Kaczorowska jm, Host ACR, and others. Coronavirus protective immunity is short-lived. June 16, 2020 (Https://www.medrxiv.org/content/10.1101/2020.05.11.20086439v2). Preprint.
44. Long QX, Tang xj, Shi qel, and others. Clinical and immunological evaluation of asymptomatic SARS-CoV-2 infection. Net made 2020 June 18 (Epub ahead of print).
45. Crank mc, Ruckward T.J., Chen M, and others. Concept proof for a structure-based vaccine design targeting RSV in humans. Science 2019; 365:505–509.
46. Graham B.S., Gilman MSA, McLennan JS. Structure-based vaccine antigen design. Annu Rev Med 2019; 70:91–104.
47. Stewart-Jones GBE, Chung Jee, Xu Ke, and others. Structure-based design of a quadrilateral fusion glycoprotein vaccine for human parainfluenza virus types 1–4. Proc Natl Acad Science USA 2018; 115:12,265–12270.
48. Loomis RJ, Stewart-Jones GBE, Tsybovsky y, and others. Structure-based design of Nippa virus vaccines: a general approach to paramyxovirus immunogen development. Immunol in front 2020; 1 1:842–842.
49. Sanders RW, Wesen M, Shuluke N, and others. Stabilization of soluble, cleaved, trimeric forms of the human immunodeficiency virus type envelope glycoprotein complex 2002; 76:8875–8889.
50. Chung Jee, Geng H, Panchara M, and others. Structure-based design of soluble prefusion-locked HIV-1 Env trimers that have improved CD4 affinity and improved immunogenicity. Jay Virol 2017; 91 (10):e02268-16–e02268-16.
51. Killikeli AM, Kanakio M, Graham B.S.. Pre-fusion is absent on the surface of F. formalin-inactivated respiratory syncytial virus. Science representative 2016, 6:34108–34108.
52. Of cars, Muramatsu H, Welsh FA, and others. Incorporation of pseudouridine into the mRNA yields improved nonimmunogenic vector with increased translational efficiency and biological stability. Mole Ther 2008; 16:1833–1840.
53. Pardee Ann, Hogan MJ, Nardikian M.S., and others. Nucleoside-modified mRNA vaccines induce potent T follicular accessory and reproductive center B cell responses. J exp 2018; 215:1571–1588.
54. Graham B.S.. Rapid COVID-19 vaccine development. Science 2020; 368:945–946.